Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review
Conclusion
With the availability of BRCA mutation-targeted therapies, identification of patients with OC with germline BRCA mutations has potential therapeutic consequences. For identified gene carriers, predictive testing to allow cancer prevention strategies, including bilateral salpingo-oophorectomy, provides wider benefit to identifying such gene carriers. Updating guidelines will increase the opportunity for targeted treatment among patients and risk reduction in relatives.
Funding
AstraZeneca
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: AstraZeneca | Breast Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | Epithelial Cancer | Genetics | Ovarian Cancer | Ovaries | Study | Women